David Scott Jones - Net Worth and Insider Trading
David Scott Jones Net Worth
The estimated net worth of David Scott Jones is at least $343,556 dollars as of 2024-11-29. David Scott Jones is the SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc and owns about 37,962 shares of EyePoint Pharmaceuticals Inc (EYPT) stock worth over $343,556. Details can be seen in David Scott Jones's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David Scott Jones has not made any transactions after 2024-02-02 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of David Scott Jones
David Scott Jones Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David Scott Jones owns 1 companies in total, including EyePoint Pharmaceuticals Inc (EYPT) .
Click here to see the complete history of David Scott Jones’s form 4 insider trades.
Insider Ownership Summary of David Scott Jones
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
EYPT | EyePoint Pharmaceuticals Inc | 2024-02-02 | SVP & Chief Commercial Officer |
David Scott Jones Latest Holdings Summary
David Scott Jones currently owns a total of 1 stock. David Scott Jones owns 37,962 shares of EyePoint Pharmaceuticals Inc (EYPT) as of February 2, 2024, with a value of $343,556.
Latest Holdings of David Scott Jones
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
EYPT | EyePoint Pharmaceuticals Inc | 2024-02-02 | 37,962 | 9.05 | 343,556 |
Holding Weightings of David Scott Jones
David Scott Jones Form 4 Trading Tracker
According to the SEC Form 4 filings, David Scott Jones has made a total of 4 transactions in EyePoint Pharmaceuticals Inc (EYPT) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in EyePoint Pharmaceuticals Inc is the sale of 209 shares on February 2, 2024, which brought David Scott Jones around $5,954.
Insider Trading History of David Scott Jones
- 1
David Scott Jones Trading Performance
David Scott Jones Ownership Network
David Scott Jones Owned Company Details
What does EyePoint Pharmaceuticals Inc do?
Who are the key executives at EyePoint Pharmaceuticals Inc?
David Scott Jones is the SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc. Other key executives at EyePoint Pharmaceuticals Inc include director & President and CEO Nancy Lurker , Chief Medical Officer Dario A. Paggiarino , and Chief Corp Dev.&Strat. Officer Michael Craig Pine .
EyePoint Pharmaceuticals Inc (EYPT) Insider Trades Summary
Over the past 18 months, David Scott Jones made 4 insider transaction in EyePoint Pharmaceuticals Inc (EYPT) with a net sale of 73,192. Other recent insider transactions involving EyePoint Pharmaceuticals Inc (EYPT) include a net sale of 943,936 shares made by Ew Healthcare Partners, L.p. , a net sale of 121,307 shares made by Dario A. Paggiarino , and a net purchase of 4,794,057 shares made by Cormorant Asset Management, Lp .
In summary, during the past 3 months, insiders sold 0 shares of EyePoint Pharmaceuticals Inc (EYPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,229,811 shares of EyePoint Pharmaceuticals Inc (EYPT) were sold and 4,817,297 shares were bought by its insiders, resulting in a net purchase of 587,486 shares.
EyePoint Pharmaceuticals Inc (EYPT)'s detailed insider trading history can be found in Insider Trading Tracker table.
EyePoint Pharmaceuticals Inc Insider Transactions
David Scott Jones Mailing Address
Above is the net worth, insider trading, and ownership report for David Scott Jones. You might contact David Scott Jones via mailing address: C/o Eyepoint Pharmaceuticals, Inc.,, 480 Pleasant Street, Suite A210, Watertown Ma 02472.